Difference between revisions of "CH Basel Uteng M"
From Bioblast
Marte Verena (talk | contribs) |
|||
| Line 1: | Line 1: | ||
{{ | {{O2k-Network Lab | ||
|institution=Novartis Pharma AG, Werk Klybeck | |institution=Novartis Pharma AG, Werk Klybeck | ||
|area code=4002 | |area code=4002 | ||
Revision as of 16:10, 9 February 2015
CH Basel Uteng M
| O2k-Network Lab | Novartis Pharma AG, Werk Klybeck |
|---|---|
| Address | , 4002 |
| City | Basel |
| State/Prov | |
| Country | Switzerland |
| Weblink | |
| Contact | |
| Team | Riebel Virginie |
| Team previous | Dong Min |
| Status | O2k 2006- |
| Oroboros Events | IOC39, IOC36 |
| Topics |
O2k-Publications
| Published | Reference | |
|---|---|---|
| Brecht 2016 Toxicol In Vitro | 2016 | Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, Krähenbühl S, Uteng M (2016) Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicol In Vitro 40:55-65. |
O2k-Abstracts
update please
- Previously CH_Muttenz_Dong M
